TENMAC EM Tenofovir Disoproxil Fumarate & Emtricitabine
- Reviews (0)
|Minimum Order Quantity||1 Bottle|
|Dose/Strength||Tenofovir Disoproxil Fumarate 300 mg Emtricitabine 200mg|
|Packaging Size||30 Tablets per Bottle|
|Composition||Tenofovir Disoproxil Fumarate 300 mg Emtricitabine 200mg|
|Brand||Mcneil and Argus Pharmaceuticals Ltd|
Each tablet contains:
Tenofovir Disoproxil Fumarate 300 mg
Do not use TENMAC-EM for pre-exposure prophylaxis in individuals with unknown or positive HIV-1 status. TENMAC-EM should be used in HIV-infected patients only in combination with other antiretroviral agents.
In HIV1 infected patients, the most common adverse reactions (incidence greater than or equal to 10%) are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. In HIV-1 uninfected individuals in PrEP trials, adverse reactions that were reported by more than 2% of TENMAC-EM subjects and more frequently than by placebo subjects were headache, abdominal pain and weight decreased.
HDPE Bottle packs of 30 tablets and packed in a unit carton along with package insert.
SHELF LIFE AND STORAGE:
24 months from the date of manufacturing, below 30°C.
- Pay Mode Terms: L/C (Letter of Credit),T/T (Bank Transfer),Other
- Port of Dispatch: Mumbai, Delhi
- Production Capacity: 10000
- Delivery Time: 7 days
- Packaging Details: 30 Tablets per Bottle